Vumerity™ Oral Capsules Approved by the FDA for Adults with Relapsing Forms of MS, Including Active SPMS https://mymsaa.org/news/vumerity-app...ent=email_body

Vumerity is in the same class of MS therapy as Biogen’s Tecfidera® (dimethyl fumarate), but is believed to cause fewer gastrointestinal (GI) side effects – such as diarrhea, nausea, vomiting, and abdominal pain. Data covering 48 weeks of treatment showed that relapse rates fell approximately 80% among the entire study group relative to baseline. In addition, the number of gadolinium-enhancing lesions seen on MRI was reduced by 77% from baseline for the entire group and by 96% from baseline for the individuals who were newly diagnosed.”